Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares were up 2.6% on Friday . The company traded as high as $11.32 and last traded at $11.28, with a volume of 194,872 shares changing hands. The stock had previously closed at $10.99.

A number of research analysts have weighed in on VNDA shares. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th. Jefferies Group reaffirmed a “buy” rating and set a $15.00 price target on shares of Vanda Pharmaceuticals in a research report on Saturday, May 7th. Finally, Brean Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Friday, May 27th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $15.92.

The company has a 50-day moving average price of $11.03 and a 200-day moving average price of $9.14. The stock’s market cap is $486.55 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.07. During the same period in the prior year, the company posted ($0.10) earnings per share. The firm had revenue of $33.30 million for the quarter, compared to analysts’ expectations of $32.48 million. Vanda Pharmaceuticals’s quarterly revenue was up 50.0% compared to the same quarter last year. Equities analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.83) EPS for the current year.

A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. J. Goldman & Co LP raised its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 20.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 902,839 shares of the biopharmaceutical company’s stock after buying an additional 151,079 shares during the period. Vanda Pharmaceuticals makes up approximately 0.9% of J. Goldman & Co LP’s holdings, making the stock its 25th largest position. J. Goldman & Co LP owned 2.11% of Vanda Pharmaceuticals worth $8,405,000 at the end of the most recent reporting period.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.